Commercialization Opps for Hybridomas

Has your research resulted in the creation of modified cell lines or hybridomas?  Building on its recent successes in out-licensing research-generated hybridomas and monoclonal antibodies to industry, the Office of Technology Transfer, (OTT),  is very interested in speaking with faculty and researchers regarding the untapped commercial potential of these cell lines, with a particular focus on hybridomas and other research tools created for your lab’s research purposes.  Additional Information: Email, 852-2965.